BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riboldi GM, Di Fonzo AB. GBA, Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells 2019;8:E364. [PMID: 31010158 DOI: 10.3390/cells8040364] [Cited by in Crossref: 58] [Cited by in F6Publishing: 83] [Article Influence: 19.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Wang X, Lin Y, Pan D. A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease. Front Mol Neurosci 2022;15:944883. [DOI: 10.3389/fnmol.2022.944883] [Reference Citation Analysis]
2 Sahin O, Thompson HP, Goodman GW, Li J, Urayama A. Mucopolysaccharidoses and the blood-brain barrier. Fluids Barriers CNS 2022;19:76. [PMID: 36117162 DOI: 10.1186/s12987-022-00373-5] [Reference Citation Analysis]
3 Riboldi GM, Vialle RA, Navarro E, Udine E, de Paiva Lopes K, Humphrey J, Allan A, Parks M, Henderson B, Astudillo K, Argyrou C, Zhuang M, Sikder T, Oriol Narcis J, Kumar SD, Janssen W, Sowa A, Comi GP, Di Fonzo A, Crary JF, Frucht SJ, Raj T. Transcriptome deregulation of peripheral monocytes and whole blood in GBA-related Parkinson's disease. Mol Neurodegener 2022;17:52. [PMID: 35978378 DOI: 10.1186/s13024-022-00554-8] [Reference Citation Analysis]
4 Vieira SRL, Schapira AHV. Glucocerebrosidase mutations and Parkinson disease. J Neural Transm (Vienna) 2022. [PMID: 35932311 DOI: 10.1007/s00702-022-02531-3] [Reference Citation Analysis]
5 Wang M, Li F, Zhang J, Lu C, Kong W. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis. J Pediatr Hematol Oncol 2022. [PMID: 35867706 DOI: 10.1097/MPH.0000000000002506] [Reference Citation Analysis]
6 Yang X, Yang R, Zhang F. Role of Nrf2 in Parkinson’s Disease: Toward New Perspectives. Front Pharmacol 2022;13:919233. [DOI: 10.3389/fphar.2022.919233] [Reference Citation Analysis]
7 Wang J, Zhao J, Hu P, Gao L, Tian S, He Z. Long Non-coding RNA HOTAIR in Central Nervous System Disorders: New Insights in Pathogenesis, Diagnosis, and Therapeutic Potential. Front Mol Neurosci 2022;15:949095. [DOI: 10.3389/fnmol.2022.949095] [Reference Citation Analysis]
8 Chiurchiù V, Tiberi M, Matteocci A, Fazio F, Siffeti H, Saracini S, Mercuri NB, Sancesario G. Lipidomics of Bioactive Lipids in Alzheimer's and Parkinson's Diseases: Where Are We? Int J Mol Sci 2022;23:6235. [PMID: 35682914 DOI: 10.3390/ijms23116235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Salles PA, Mata IF, Fernandez HH. Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation. Parkinsonism Relat Disord 2022;99:96-8. [PMID: 35461777 DOI: 10.1016/j.parkreldis.2022.04.006] [Reference Citation Analysis]
10 Schalkamp AK, Rahman N, Monzón-Sandoval J, Sandor C. Deep phenotyping for precision medicine in Parkinson's disease. Dis Model Mech 2022;15:dmm049376. [PMID: 35647913 DOI: 10.1242/dmm.049376] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xiao Y, Chen H, Liao J, Zhang Q, He H, Lei J, Huang J, Ouyang Q, Shen Y, Wang J. The Potential Circular RNAs Biomarker Panel and Regulatory Networks of Parkinson’s Disease. Front Neurosci 2022;16:893713. [DOI: 10.3389/fnins.2022.893713] [Reference Citation Analysis]
12 Ma M, Moulton MJ, Lu S, Bellen HJ. 'Fly-ing' from rare to common neurodegenerative disease mechanisms. Trends Genet 2022:S0168-9525(22)00080-4. [PMID: 35484057 DOI: 10.1016/j.tig.2022.03.018] [Reference Citation Analysis]
13 Esfandiary A, Finkelstein DI, Voelcker NH, Rudd D. Clinical Sphingolipids Pathway in Parkinson’s Disease: From GCase to Integrated-Biomarker Discovery. Cells 2022;11:1353. [DOI: 10.3390/cells11081353] [Reference Citation Analysis]
14 Segur-Bailach E, Ugarteburu O, Tort F, Texido L, Painous C, Compta Y, Martí MJ, Ribes A, Gort L. Over-Mutated Mitochondrial, Lysosomal and TFEB-Regulated Genes in Parkinson's Disease. J Clin Med 2022;11:1749. [PMID: 35330074 DOI: 10.3390/jcm11061749] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kim GJ, Mo H, Liu H, Okorie M, Chen S, Zheng J, Li H, Arkin M, Huang B, Guo S. In Vivo Dopamine Neuron Imaging-Based Small Molecule Screen Identifies Novel Neuroprotective Compounds and Targets. Front Pharmacol 2022;13:837756. [DOI: 10.3389/fphar.2022.837756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Berdowska I, Matusiewicz M, Krzystek-korpacka M. HDL Accessory Proteins in Parkinson’s Disease—Focusing on Clusterin (Apolipoprotein J) in Regard to Its Involvement in Pathology and Diagnostics—A Review. Antioxidants 2022;11:524. [DOI: 10.3390/antiox11030524] [Reference Citation Analysis]
17 Tönges L, Kwon EH, Klebe S. Monogenetic Forms of Parkinson’s Disease – Bridging the Gap Between Genetics and Biomarkers. Front Aging Neurosci 2022;14:822949. [DOI: 10.3389/fnagi.2022.822949] [Reference Citation Analysis]
18 Kwon EH, Tennagels S, Gold R, Gerwert K, Beyer L, Tönges L. Update on CSF Biomarkers in Parkinson's Disease. Biomolecules 2022;12:329. [PMID: 35204829 DOI: 10.3390/biom12020329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Pang SY, Lo RCN, Ho PW, Liu H, Chang EES, Leung C, Malki Y, Choi ZY, Wong WY, Kung MH, Ramsden DB, Ho S. LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Transl Neurodegener 2022;11. [DOI: 10.1186/s40035-022-00281-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ho D, Schierding W, Farrow SL, Cooper AA, Kempa-Liehr AW, O'Sullivan JM. Machine Learning Identifies Six Genetic Variants and Alterations in the Heart Atrial Appendage as Key Contributors to PD Risk Predictivity. Front Genet 2021;12:785436. [PMID: 35047012 DOI: 10.3389/fgene.2021.785436] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Napolioni V, Fredericks CA, Kim Y, Channappa D, Khan RR, Kim LH, Zafar F, Couthouis J, Davidzon GA, Mormino EC, Gitler AD, Montine TJ, Schüle B, Greicius MD. Phenotypic Heterogeneity among GBA p.R202X Carriers in Lewy Body Spectrum Disorders. Biomedicines 2022;10:160. [DOI: 10.3390/biomedicines10010160] [Reference Citation Analysis]
22 Kishnani PS, Al-Hertani W, Balwani M, Göker-Alpan Ö, Lau HA, Wasserstein M, Weinreb NJ, Grabowski G. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: Results from a Delphi consensus. Mol Genet Metab 2021:S1096-7192(21)01194-X. [PMID: 34972655 DOI: 10.1016/j.ymgme.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Lama J, Buhidma Y, Fletcher E, Duty S. Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research. Neuronal Signaling 2021;5:NS20210026. [DOI: 10.1042/ns20210026] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Yalçin M, Malhan D, Basti A, Peralta AR, Ferreira JJ, Relógio A. A Computational Analysis in a Cohort of Parkinson's Disease Patients and Clock-Modified Colorectal Cancer Cells Reveals Common Expression Alterations in Clock-Regulated Genes. Cancers (Basel) 2021;13:5978. [PMID: 34885088 DOI: 10.3390/cancers13235978] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Torres M, Parets S, Fernández-Díaz J, Beteta-Göbel R, Rodríguez-Lorca R, Román R, Lladó V, Rosselló CA, Fernández-García P, Escribá PV. Lipids in Pathophysiology and Development of the Membrane Lipid Therapy: New Bioactive Lipids. Membranes (Basel) 2021;11:919. [PMID: 34940418 DOI: 10.3390/membranes11120919] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
26 Fishman PS, Fischell JM. Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases. Front Neurol 2021;12:749047. [PMID: 34803886 DOI: 10.3389/fneur.2021.749047] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
27 Mata IF. Navigating the open sea of commercial genetic testing in Parkinson's disease. Parkinsonism Relat Disord 2021;92:105-6. [PMID: 34774427 DOI: 10.1016/j.parkreldis.2021.10.027] [Reference Citation Analysis]
28 Elsayed I, Martinez-Carrasco A, Cornejo-Olivas M, Bandres-Ciga S. Mapping the Diverse and Inclusive Future of Parkinson's Disease Genetics and Its Widespread Impact. Genes (Basel) 2021;12:1681. [PMID: 34828286 DOI: 10.3390/genes12111681] [Reference Citation Analysis]
29 Pirooznia SK, Rosenthal LS, Dawson VL, Dawson TM. Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection. Pharmacol Rev 2021;73:33-97. [PMID: 34663684 DOI: 10.1124/pharmrev.120.000189] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
30 Higgins AL, Toffoli M, Mullin S, Lee CY, Koletsi S, Avenali M, Blandini F, Schapira AH. The remote assessment of parkinsonism supporting ongoing development of interventions in Gaucher disease. Neurodegener Dis Manag 2021. [PMID: 34666501 DOI: 10.2217/nmt-2021-0032] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
31 Fischell JM, Fishman PS. A Multifaceted Approach to Optimizing AAV Delivery to the Brain for the Treatment of Neurodegenerative Diseases. Front Neurosci 2021;15:747726. [PMID: 34630029 DOI: 10.3389/fnins.2021.747726] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
32 Guadagnolo D, Piane M, Torrisi MR, Pizzuti A, Petrucci S. Genotype-Phenotype Correlations in Monogenic Parkinson Disease: A Review on Clinical and Molecular Findings. Front Neurol 2021;12:648588. [PMID: 34630269 DOI: 10.3389/fneur.2021.648588] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Riboldi GM, Frattini E, Monfrini E, Frucht SJ, Fonzo AD. A Practical Approach to Early-Onset Parkinsonism. J Parkinsons Dis 2021. [PMID: 34569973 DOI: 10.3233/JPD-212815] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Kim GJ, Mo H, Liu H, Wu Z, Chen S, Zheng J, Zhao X, Nucum D, Shortland J, Peng L, Elepano M, Tang B, Olson S, Paras N, Li H, Renslo AR, Arkin MR, Huang B, Lu B, Sirota M, Guo S. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons. Elife 2021;10:e69795. [PMID: 34550070 DOI: 10.7554/eLife.69795] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Johnson ME, Bergkvist L, Stetzik L, Steiner JA, Meyerdirk L, Schulz E, Wolfrum E, Luk KC, Wesson DW, Krainc D, Brundin P. Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological α-synuclein spread in the prodromal preformed fibrils model in young mice. Neurobiol Dis 2021;159:105513. [PMID: 34536552 DOI: 10.1016/j.nbd.2021.105513] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
36 Dumitrascu DL. Gaucher disease: an update. Med Pharm Rep 2021;94:S54-6. [PMID: 34527912 DOI: 10.15386/mpr-2231] [Reference Citation Analysis]
37 Bindas AJ, Kulkarni S, Koppes RA, Koppes AN. Parkinson's disease and the gut: Models of an emerging relationship. Acta Biomater 2021;132:325-44. [PMID: 33857691 DOI: 10.1016/j.actbio.2021.03.071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Mahmoud M, Doddapaneni H, Timp W, Sedlazeck FJ. PRINCESS: comprehensive detection of haplotype resolved SNVs, SVs, and methylation. Genome Biol 2021;22:268. [PMID: 34521442 DOI: 10.1186/s13059-021-02486-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Teixeira M, Sheta R, Idi W, Oueslati A. Alpha-Synuclein and the Endolysosomal System in Parkinson's Disease: Guilty by Association. Biomolecules 2021;11:1333. [PMID: 34572546 DOI: 10.3390/biom11091333] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
40 Bastien J, Menon S, Messa M, Nyfeler B. Molecular targets and approaches to restore autophagy and lysosomal capacity in neurodegenerative disorders. Mol Aspects Med 2021;:101018. [PMID: 34489092 DOI: 10.1016/j.mam.2021.101018] [Reference Citation Analysis]
41 Ledda C, Artusi CA, Montanaro E, Martone T, Zibetti M, Lopiano L. G325R GBA mutation in Parkinson's disease: Disease course and long-term DBS outcome. Brain Stimul 2021;14:1169-71. [PMID: 34375692 DOI: 10.1016/j.brs.2021.08.002] [Reference Citation Analysis]
42 Fais M, Dore A, Galioto M, Galleri G, Crosio C, Iaccarino C. Parkinson's Disease-Related Genes and Lipid Alteration. Int J Mol Sci 2021;22:7630. [PMID: 34299248 DOI: 10.3390/ijms22147630] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Vuletić V, Rački V, Papić E, Peterlin B. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics? Int J Mol Sci 2021;22:7213. [PMID: 34281267 DOI: 10.3390/ijms22137213] [Reference Citation Analysis]
44 Menozzi E, Schapira AHV. Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 2021;12:694764. [PMID: 34248830 DOI: 10.3389/fneur.2021.694764] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
45 Abeliovich A, Hefti F, Sevigny J. Gene Therapy for Parkinson's Disease Associated with GBA1 Mutations. J Parkinsons Dis 2021. [PMID: 34151863 DOI: 10.3233/JPD-212739] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zampieri S, Cattarossi S, Pavan E, Barbato A, Fiumara A, Peruzzo P, Scarpa M, Ciana G, Dardis A. Accurate Molecular Diagnosis of Gaucher Disease Using Clinical Exome Sequencing as a First-Tier Test. Int J Mol Sci 2021;22:5538. [PMID: 34073924 DOI: 10.3390/ijms22115538] [Reference Citation Analysis]
47 Racki V, Papic E, Almahariq F, Chudy D, Vuletic V. The Successful Three-Year Outcome of Deep Brain Stimulation in Gaucher Disease Type 1 Associated Parkinson's Disease: A Case Report. Mov Disord Clin Pract 2021;8:604-6. [PMID: 33981795 DOI: 10.1002/mdc3.13185] [Reference Citation Analysis]
48 Grenn FP, Moore A, Bandres-Ciga S, Krohn L, Blauwendraat C; International Parkinson's Disease Genomics Consortium (IPDGC). Assessment of ANG variants in Parkinson's disease. Neurobiol Aging 2021;104:111.e1-4. [PMID: 33875291 DOI: 10.1016/j.neurobiolaging.2021.03.006] [Reference Citation Analysis]
49 Shen L, Wang C, Chen L, Wong G. Dysregulation of MicroRNAs and PIWI-Interacting RNAs in a Caenorhabditis elegans Parkinson's Disease Model Overexpressing Human α-Synuclein and Influence of tdp-1. Front Neurosci 2021;15:600462. [PMID: 33762903 DOI: 10.3389/fnins.2021.600462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
50 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
51 Behl T, Kaur G, Fratila O, Buhas C, Judea-pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10. [DOI: 10.1186/s40035-020-00226-x] [Reference Citation Analysis]
52 Terranova DA, Giraldo LJM, Idrobo H, Satizabal JM. Molecular Characterization of the GBA Gene in Patients from Southwest of Colombia with Gaucher Disease. J inborn errors metab screen 2021;9:e20200018. [DOI: 10.1590/2326-4594-jiems-2020-0018] [Reference Citation Analysis]
53 Muñoz SS, Petersen D, Marlet FR, Kücükköse E, Galvagnion C. The interplay between Glucocerebrosidase, α-synuclein and lipids in human models of Parkinson's disease. Biophys Chem 2021;273:106534. [PMID: 33832803 DOI: 10.1016/j.bpc.2020.106534] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
54 Akiyama T, Sato S, Ko SBH, Sano O, Sato S, Saito M, Nagai H, Ko MSH, Iwata H. Synthetic mRNA-based differentiation method enables early detection of Parkinson's phenotypes in neurons derived from Gaucher disease-induced pluripotent stem cells. Stem Cells Transl Med 2021;10:572-81. [PMID: 33342090 DOI: 10.1002/sctm.20-0302] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Dahl M, Smith EMK, Warsi S, Rothe M, Ferraz MJ, Aerts JMFG, Golipour A, Harper C, Pfeifer R, Pizzurro D, Schambach A, Mason C, Karlsson S. Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector. Mol Ther Methods Clin Dev 2021;20:312-23. [PMID: 33511245 DOI: 10.1016/j.omtm.2020.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Lin TK, Lin KJ, Lin KL, Liou CW, Chen SD, Chuang YC, Wang PW, Chuang JH, Wang TJ. When Friendship Turns Sour: Effective Communication Between Mitochondria and Intracellular Organelles in Parkinson's Disease. Front Cell Dev Biol 2020;8:607392. [PMID: 33330511 DOI: 10.3389/fcell.2020.607392] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
57 García-Sanz P, M F G Aerts J, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2021;36:1070-85. [PMID: 33219714 DOI: 10.1002/mds.28396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
58 Desplanque M, Bonte MA, Gressier B, Devos D, Chartier-Harlin MC, Belarbi K. Trends in Glucocerebrosides Research: A Systematic Review. Front Physiol 2020;11:558090. [PMID: 33192552 DOI: 10.3389/fphys.2020.558090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 von Linstow CU, Gan-Or Z, Brundin P. Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. Transl Neurodegener 2020;9:39. [PMID: 33066808 DOI: 10.1186/s40035-020-00218-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
60 Nikolova D, Yordanov A, Damyanova V, Yavorova A, Radinov A. Gaucher Disease Type I: A Case Report. Acta Medica Bulgarica 2020;47:22-5. [DOI: 10.2478/amb-2020-0029] [Reference Citation Analysis]
61 Weill Y, Zimran A, Zadok D, Wasser LM, Revel-Vilk S, Hanhart J, Dinur T, Arkadir D, Becker-Cohen M. Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease. Int J Mol Sci 2020;21:E7027. [PMID: 32987733 DOI: 10.3390/ijms21197027] [Reference Citation Analysis]
62 Di Rocco M, Di Fonzo A, Barbato A, Cappellini MD, Carubbi F, Giona F, Giuffrida G, Linari S, Pession A, Quarta A, Scarpa M, Spada M, Strisciuglio P, Andria G. Parkinson's disease in Gaucher disease patients: what's changing in the counseling and management of patients and their relatives? Orphanet J Rare Dis 2020;15:262. [PMID: 32967694 DOI: 10.1186/s13023-020-01529-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
63 Kakouri AC, Votsi C, Tomazou M, Minadakis G, Karatzas E, Christodoulou K, Spyrou GM. Analyzing Gene Expression Profiles from Ataxia and Spasticity Phenotypes to Reveal Spastic Ataxia Related Pathways. Int J Mol Sci 2020;21:E6722. [PMID: 32937819 DOI: 10.3390/ijms21186722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Tantawy AAG, Adly AAM, Hashem NH, Ebeid WM, Abdeen MS, Salah NY. Ganglion Cell Complex Thinning in Young Gaucher Patients: Relation to Prodromal Parkinsonian Markers. Mov Disord 2020;35:2211-9. [PMID: 32918500 DOI: 10.1002/mds.28256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Aubignat M, Tir M, Krystkowiak P. [Non-motor symptoms of Parkinson's disease from pathophysiology to early diagnosis]. Rev Med Interne 2021;42:251-7. [PMID: 32680717 DOI: 10.1016/j.revmed.2020.06.019] [Reference Citation Analysis]
66 Menozzi E, Schapira AHV. Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs 2020;34:915-23. [PMID: 32607746 DOI: 10.1007/s40263-020-00746-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
67 Siokas V, Aloizou AM, Tsouris Z, Liampas I, Aslanidou P, Dastamani M, Brotis AG, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E. Genetic Risk Factors for Essential Tremor: A Review. Tremor Other Hyperkinet Mov (N Y) 2020;10:4. [PMID: 32775018 DOI: 10.5334/tohm.67] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Yang W, Li X, Yin N. Increased α-synuclein oligomerization is associated with decreased activity of glucocerebrosidase in the aging human striatum and hippocampus. Neurosci Lett 2020;733:135093. [PMID: 32470554 DOI: 10.1016/j.neulet.2020.135093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Zulueta A, Mingione A, Signorelli P, Caretti A, Ghidoni R, Trinchera M. Simple and Complex Sugars in Parkinson's Disease: a Bittersweet Taste. Mol Neurobiol 2020;57:2934-43. [PMID: 32430844 DOI: 10.1007/s12035-020-01931-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Marsili L, Vizcarra JA, Sturchio A, Dwivedi AK, Keeling EG, Patel D, Mishra M, Farooqi A, Merola A, Fasano A, Mata IF, Kauffman MA, Espay AJ. When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. J Neurol 2021;268:3203-11. [PMID: 32436106 DOI: 10.1007/s00415-020-09892-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
71 Váradi C. Clinical Features of Parkinson's Disease: The Evolution of Critical Symptoms. Biology (Basel) 2020;9:E103. [PMID: 32438686 DOI: 10.3390/biology9050103] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
72 Zhang T, Peterson RT. Modeling Lysosomal Storage Diseases in the Zebrafish. Front Mol Biosci 2020;7:82. [PMID: 32435656 DOI: 10.3389/fmolb.2020.00082] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
73 Marchi G, Nascimbeni F, Motta I, Busti F, Carubbi F, Cappellini MD, Pietrangelo A, Corradini E, Piperno A, Girelli D. Hyperferritinemia and diagnosis of type 1 Gaucher disease. Am J Hematol 2020;95:570-6. [PMID: 32031266 DOI: 10.1002/ajh.25752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
74 Favret JM, Weinstock NI, Feltri ML, Shin D. Pre-clinical Mouse Models of Neurodegenerative Lysosomal Storage Diseases. Front Mol Biosci 2020;7:57. [PMID: 32351971 DOI: 10.3389/fmolb.2020.00057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 Tantawy AAG, Adly AAM, Abdeen MSED, Salah NY. Cognitive decline and depressive symptoms: early non-motor presentations of parkinsonism among Egyptian Gaucher patients. Neurogenetics 2020;21:159-67. [DOI: 10.1007/s10048-020-00607-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
76 Miyaue N, Yabe H, Nagai M. Serum growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease. Journal of the Neurological Sciences 2020;409:116616. [DOI: 10.1016/j.jns.2019.116616] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
77 Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P. Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study. Mov Disord 2020;35:672-8. [PMID: 31912918 DOI: 10.1002/mds.27971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
78 Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci 2020;21:103-15. [DOI: 10.1038/s41583-019-0257-7] [Cited by in Crossref: 57] [Cited by in F6Publishing: 88] [Article Influence: 28.5] [Reference Citation Analysis]
79 Moraes BJ, Coelho P, Fão L, Ferreira IL, Rego AC. Modified Glutamatergic Postsynapse in Neurodegenerative Disorders. Neuroscience 2021;454:116-39. [PMID: 31887357 DOI: 10.1016/j.neuroscience.2019.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
80 Graham OEE, Pitcher TL, Liau Y, Miller AL, Dalrymple-Alford JC, Anderson TJ, Kennedy MA. Nanopore sequencing of the glucocerebrosidase (GBA) gene in a New Zealand Parkinson's disease cohort. Parkinsonism Relat Disord 2020;70:36-41. [PMID: 31809948 DOI: 10.1016/j.parkreldis.2019.11.022] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
81 Lin KJ, Lin KL, Chen SD, Liou CW, Chuang YC, Lin HY, Lin TK. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease. Int J Mol Sci 2019;20:E5312. [PMID: 31731450 DOI: 10.3390/ijms20215312] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 17.7] [Reference Citation Analysis]
82 Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clin Geriatr Med 2020;36:1-12. [PMID: 31733690 DOI: 10.1016/j.cger.2019.08.002] [Cited by in Crossref: 66] [Cited by in F6Publishing: 65] [Article Influence: 22.0] [Reference Citation Analysis]
83 Indellicato R, Trinchera M. The Link between Gaucher Disease and Parkinson's Disease Sheds Light on Old and Novel Disorders of Sphingolipid Metabolism. Int J Mol Sci 2019;20:E3304. [PMID: 31284408 DOI: 10.3390/ijms20133304] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]